A change in coverage could put pressure on other insurance companies to expand access
A Phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023 (Jastreboff et al., NEJM 2023) reported that participants receiving higher doses of retatrutide (up to 12 mg) achieved mean body weight reductions of approximately 1724% over 48 weeks
Being overweight isn't always unhealthy but one kind of fat is While BMI or body mass index has long been used to measure obesity, Kessler is among a growing number of scientists who say it's not a helpful indicator of health
This was evidenced by increased alkaline phosphatase (ALP) activity, enhanced mineralization, and upregulation of osteogenic markers such as osteocalcin (OCN) and Runt-related transcription factor 2 (RUNX2)
In a major clinical trial published in The New England Journal of Medicine , patients taking retatrutide lost an average of about 24% of their body weight after 48 weeks
The results with Retatrutide were simply in a different category from anything else I had used
